Exagen: A Small Diagnostics Company Approaching An Inflection Point
Exagen Inc XGN
$4.53
▼ -3.00%
($-0.14)
🎢 High Beta
📅 Earnings This Week
Open
$4.62
Prev Close
$4.67
Day Range
$4.38 – $4.72
52W Range
$2.59 – $12.23
Market Cap
$112.83M
Beta
2.05
EPS (TTM)
$-0.88
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-09-19 |
| Shares Out. | 24,160,000 |
| Website | exagen.com/ ↗ |
| Phone | 13026587581 |
| Employees | 220 |
| Revenue | $17.3M |
| Gross Profit | $10.2M |
| Net Income | -$4.0M |
| Free Cash Flow | -$14.1M |
| Total Assets | $52.0M |
| Total Liabilities | $37.5M |
| Equity | $14.4M |
About Exagen Inc
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Exagen Inc is a publicly traded company under the ticker symbol XGN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)